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ABSTRACT
EphB4 is a membrane-bound receptor tyrosine kinase (RTK) commonly over-
produced by many epithelial cancers but with low to no expression in most normal 
adult tissues. EphB4 over-production promotes ligand-independent signaling 
pathways that increase cancer cell viability and stimulate migration and invasion. 
Several studies have shown that normal ligand-dependent signaling is tumour 
suppressive and therefore novel therapeutics which block the tumour promoting 
ligand-independent signaling and/or stimulate tumour suppressive ligand-dependent 
signaling will find application in the treatment of cancer. An EphB4-specific polyclonal 
antibody, targeting a region of 200 amino acids in the extracellular portion of EphB4, 
showed potent in vitro anti-cancer effects measured by an increase in apoptosis and a 
decrease in anchorage independent growth. Peptide exclusion was used to identify the 
epitope targeted by this antibody within the cysteine-rich region of the EphB4 protein, 
a sequence defined as a potential ligand interacting interface. Addition of antibody 
to cancer cells resulted in phosphorylation and subsequent degradation of the EphB4 
protein, suggesting a mechanism that is ligand mimetic and tumour suppressive. 
A monoclonal antibody which specifically targets this identified extracellular epitope 
of EphB4 significantly reduced breast cancer xenograft growth in vivo confirming that 
EphB4 is a useful target for ligand-mimicking antibody-based anti-cancer therapies.
INTRODUCTION
EphB4 is a member of the largest family of 
receptor tyrosine kinases and is an important regulator 
of fundamental physiological and pathophysiological 
processes such as tissue patterning during development, 
angiogenesis and tumour progression [1]. Despite 
significant promiscuity between other Eph family members 
and the ephrin ligands, the single physiologically-relevant 
ligand of the EphB4 receptor is ephrin-B2 [2]. Both the 
receptor and the ligand are membrane-bound but usually 
expressed on neighbouring cells. Forward signaling, 
through EphB4, and reverse signaling, through ephrin-B2, 
requires heterotetramerisation of two receptors on one cell 
with two ligands on a neighbouring cell [3]. This normal 
interaction between EphB4 and ephrin-B2 therefore 
requires direct cell-cell contact and induces forward 
signaling of the receptor that leads to tumour suppression 
and reverse signaling through the ligand that stabilizes 
cell-cell adhesion and can stimulate angiogenesis if the 
ephrin-B2 expressing cell is an endothelial cell [3].
Changes to the normal Eph-ephrin balance, for 
example to high EphB4 and low ephrin-B2, disrupts 
normal ligand-dependent signaling and promotes 
ligand-independent-mediated mechanisms that drive 
tumourigenesis [4–5]. Most commonly, the EphB4/
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ephrin-B2 balance in many cancer cells is disrupted by 
over-expression of the EphB4 receptor. EphB4 is reported 
as over-expressed in many epithelial cancers including, but 
not limited to, prostate (66% of cases studied) [6–7], colon 
(63–100%) [8–10], breast (58–94%) [11–15], ovarian 
(80–100%) [16–18], endometrial (100%) [19], pancreatic 
(100%) [20], lung (100%) [21] and cervical cancers (95%) 
[22–23]. Combining the data from these studies, currently 
to date, EphB4 protein levels have been tested in 1318 
individual tumour samples and is increased above the level 
in normal matched tissues in 1046 (82%) of these. The 
mechanisms that drive EphB4 over-expression in cancer 
cells have not been determined although EphB4 itself was 
recently reported to regulate the estrogen receptor α and 
vimentin in breast cancer [24–25]. Amplification of the 
EphB4 gene has also been reported in clinical samples and 
cell lines from several cancer tissues including prostate, 
breast, bladder and head and neck [6, 11, 26–27].
The critical importance of EphB4 in tumour progression 
is demonstrated by studies using over-expression and 
knockdown strategies [6, 11, 28]. Forced over-expression of 
EphB4 in non-tumorigenic MCF10A breast cells and in 22Rv1 
prostate cancer cells led to transformation of the MCF10A line 
and increased the metastatic phenotype of the 22Rv1 cells 
[28]. Addition of soluble clustered ligand abrogated these 
effects supporting a hypothesis that over-expression of EphB4 
activates ligand-independent tumour promotion pathways 
and that ephrin-B2 ligand stimulation is tumour suppressive. 
Correspondingly, knockdown of EphB4 in several cancer cell 
lines consistently resulted in a 70–80% reduction in cancer 
cell viability, an 8–16 fold increase in apoptosis and up to 
an 80% reduction in cell migration and invasion [6, 11]. 
Furthermore, in vivo experiments targeting xenograft tumour 
cells expressing EphB4 using anti-sense oligonucleotides 
and monoclonal antibodies have demonstrated significant 
inhibition of tumour growth [6, 10, 11, 16].
EphB4/ephrinB2 bidirectional signaling has an 
established role in the formation of the vascular system, 
as evidenced by embryonic lethality in knockout mouse 
studies due to malformed vascular architecture [29–30] and 
functional experiments that show the critical requirement 
for bidirectional signaling for arteriovenous differentiation 
[31–32]. Given the importance of angiogenesis to tumour 
growth, several groups have explored the roles of EphB4 
in this process, many using over-expression strategies to 
reconstruct or block either forward or reverse signaling 
with signaling defective mutants, soluble extracellular 
domain proteins, antibodies or small molecule inhibitors 
[33–38]. Tumour cells expressing dominant negative 
EphB4 incapable of forward signaling but able to stimulate 
ephrin-B2 reverse signaling, attracted endothelial cells, 
stimulating cell invasion, survival and proliferation and 
this correlated with tumours with larger blood vessels and 
a higher blood content [33]. Soluble monomeric EphB4 
can block tumour angiogenesis and is being explored as 
anti-tumour therapeutics [34–35]. Similarly, antibodies 
that target ephrin-B2 and the extracellular fibronectin 
type III domains of EphB4 have been shown to modulate 
angiogenesis and inhibit tumour growth by mechanisms 
that are still unclear [36–37].
We used a peptide exclusion approach to identify 
an epitope within the extracellular cysteine-rich domain 
of EphB4 that is targeted by a commercially available 
polyclonal antibody with in vitro anti-cancer effects [39]. 
A panel of antibodies raised to a peptide including this 
epitope also show similar anti-cancer effects, including 
inhibition of the growth of established tumours and reduction 
of tumour mass. These studies have established EphB4 as a 
key target for the development of new anti-cancer therapies 
to which significant effort should be directed.
RESULTS
Validation of the H200 anti-EphB4 polyclonal 
antibody
The commercial H200 polyclonal antibody (Santa 
Cruz) was raised to a 200 amino acid sequence in the 
extracellular domain of human EphB4 that spans the 
cysteine-rich region and the first fibronectin type III 
repeat (Figure 1A). To confirm that this antibody can 
identify EphB4 we compared the non-transformed breast 
cell line MCF10A which expresses a low endogenous 
level of EphB4 with MCF10A cells engineered to over-
express full length EphB4 (MCF10A-B4) using three 
different techniques. Initially cell surface expression of 
EphB4 in both the parental and derivative was compared 
by flow cytometry. A clear increase in fluorescence of 
the MCF10A-B4 when compared with the MCF10A 
cells (green peak shifted to right) shows that the H200 
polyclonal antibody (Ab) is binding to surface expressed 
EphB4 in the MCF10A–B4 cells (Figure 1B). The 
H200 pAb was then used in Western blot analysis using 
total protein isolates extracted from both cell lines. A 
strongly immunoreactive band at the predicted molecular 
weight of EphB4 (120 kDa) was detected with the H200 
antibody in the sample from the MCF10A-B4 cells 
compared to low expressing control empty vector only 
MCF10A-VO cells (VO) (Figure 1C). Finally, EphB4 was 
detected in MCF10A-VO and MCF10A-B4 cells using 
immunofluorescence (Figure 1D). The increased green 
fluorescence in the MCF10A-B4 cells when compared 
with MCF10A-VO cells indicates that the H200 pAb 
recognizes over-expressed EphB4 protein. Together these 
results show that the H200 pAb recognizes EphB4.
H200 pAb targets extracellular EphB4 and 
causes the death of tumour cells grown in vitro
H200 pAb was added to confluent monolayers of 
the EphB4 positive colon cancer cell line SW480. After 
24 h, the edge of the confluent monolayer had separated 
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Figure 1: Validation of the EphB4-specific antibody H200 and its effect on cancer cell growth in vitro. (A) The H200 
antibody recognizes a 200 amino acid sequence in the extracellular domain of EphB4 spanning the cysteine rich domain (CYS) and the 
first fibronectin type III repeat (FIII). LBD—globular ligand binding domain, SAM—sterile alpha motif, PDZ—PDZ domain. (B) Flow 
cytometry comparing parental MCF10A cells with EphB4 over-expressing MCF10A-B4 cells using the H200 antibody showing an increase 
in fluorescence of the EphB4 over-expressing cells. (C) Western blot analysis with the H200 antibody identifying EphB4 over-expressed 
in the MCF10A-B4 cells (B4) compared with the parental empty vector only MCF10A-VO cells. β-actin was used to demonstrate equal 
loading. (D) Immunofluorescence using the H200 antibody to identify EphB4 (green) over-expressed in the MCF10A-B4 cells compared 
to the parental cells transfected with the empty vector (VO). Phalloidin-TRITC (red) stains F-actin, DAPI (blue) stains the nucleus. 
Co-localisation of EphB4 and F-actin (yellow). Bar = 10 μm. (E) Photomicrographs of cells treated with 0.4 μg/ml H200 antibody added 
to confluent monolayers of SW480 colon cancer cells for different lengths of time. (F) Trypan blue assay of SW480 cells treated with four 
different EphB4-specific antibodies for 48 h. Antibodies included the Ziemiecki lab rabbit polyclonal antibody (S), EphB4 (N-19) (N), 
EphB4 (H-200) (H) and EphB4 (C-16) (C) all from Santa Cruz Biotechnology. The H200 antibody showed a reduction in the number of 
viable cells compared to the control untreated (Con) and the other three antibodies irrespective of the presence (FCS) or absence (CLM) of 
complement. (G) Trypan blue assay of SW480 cells treated with either 0.2 μg/ml or 1 μg/ml H200 for 48 or 72 h. A significant reduction in 
the number of viable cells was seen at 72 h with the low concentration ( p < 0.05) and at 48 h with the higher concentration ( p < 0.001), with 
no viable cells remaining after 72 h treatment with 1 μg/ml H200. (H) Caspase-3 assay of SW480 cells treated with different concentrations 
of H200 (as per Figure 1G). The reduction in cell viability correlates with an increase in caspase-3 activity, statistically significant at 72 h 
with 0.2 μg/ml ( p = 0.002) and at 48 h with 1 μg/ml ( p = 0.003).
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from the bottom of the tissue culture well (Figure 1E). 
At 48 h the sheet of cells was completely lifted and gentle 
agitation caused the fragile sheet to begin to break apart. 
By 72 h cells were present either separately or in small 
clusters and > 80% stained with trypan blue indicating cell 
death. To determine if this was a specific response of the 
cells to the H200 antibody, three other antibodies targeting 
EphB4 were also tested. In this assay, treatment with H200 
reduced cell viability to approximately 20% ( p = 0.0006) 
whereas treatment with the Swiss pAb (S) reduced cell 
viability to approximately 70% ( p = 0.006) (Figure 1F). 
No significant effect was seen after addition of the other 
Santa Cruz polyclonal antibody preparations that target 
different regions of the EphB4 protein (N-19 targets 
an N-terminal extracellular epitope and C-16 targets a 
C-terminal intracellular epitope) (Figure 1F). This suggests 
that this H200-induced decreased viability response is 
mediated through an epitope in the extracellular part of 
EphB4 recognised by antibodies in the H200 polyclonal 
antibody preparations. To test whether the H200 response 
was complement-mediated, heat-inactivated fetal calf 
serum (complement limited medium (CLM)) was 
compared with medium containing 10% complement-
active normal fetal calf serum (FCS). The antibody effect 
was the same in both conditions showing that complement 
does not play a role in this response (Figure 1F).
The H200-mediated tumour cell death response 
is dose-dependent and induces apoptosis
To determine the mode of cell death caused by the 
H200 antibody, confluent SW480 cells were incubated 
with two different dilutions of H200 antibody (final 
concentrations 1 μg/ml and 0.2 μg/ml) and viability was 
again assessed at two different time points (48 h and 
72 h) using a trypan blue exclusion assay. Increasing 
concentrations of antibody resulted in more cells staining 
with trypan blue, suggestive of a dose-dependent antibody 
cell death response (Figure 1G). There were no viable cells 
after treatment with 1 μg/ml H200 for 72 h. To determine 
the general mechanism of cell death, we used both a 
caspase-3 activity assay as an indicator of apoptosis and an 
LDH activity assay as a measure of general cell toxicity. 
A concomitant and significant increase in caspase-3 
activity, with no change in LDH activity suggests that 
the mechanism of cell death was through induction of 
apoptosis (Figure 1H and data not shown).
EphB4-specific H200 broadly targets EphB4-
positive tumour cells
To confirm that the effect seen in SW480 cells after 
addition of the H200 antibody was not specific to this 
colon cancer cell line only, the experiments using H200 
were repeated using confluent monolayers of various 
cancer cell lines including colon cancer cell line (SW620), 
breast cancer cell lines (MDA-MB-231, MCF-7), bladder 
cancer cell lines (T24, HT119), prostate cancer cell lines 
(PC3, LNCaP), the non-transformed breast cell line 
MCF10A, primary human umbilical vein endothelial cells 
(HUVEC) and osteosarcoma cell lines (BTK143, MG63). 
Significantly decreased viability was seen in most cancer 
cell lines after antibody treatment with the exception of 
T24, LNCaP and MG63 (Figure 2A). The non-transformed 
breast line MCF10A and normal HUVEC, both EphB4 
positive [32, 40], were also unaffected (Figure 2A).
The EphB4 antibody inhibits anchorage 
independent growth and tubular network 
formation of cancer cells
The ability to form colonies in soft agar (anchorage-
independent) and tubular network formation on Matrigel 
are sensitive indicators of metastatic potential for cancer 
cell lines [41–42]. MCF10A breast epithelial cells and 
breast cancer cell lines MDA-MB-231 and MDA-MB-468 
were grown suspended in soft agar. Addition of the Ab 
significantly ( p < 0.001) inhibited the number of colonies 
formed by the two invasive cell lines MDA-MB-231 and 
MDA-MB-468 by 57% and 70% respectively, compared 
with vehicle-treated controls (Figure 2B). Colonies were 
also smaller in size in the antibody treated samples. The 
MCF10A cells did not form colonies in soft agar (remained 
as single viable cells), as expected, and were not affected 
by the presence of the antibody. For the Matrigel assay, 
four different cell lines with distinct 3D morphologies 
(MCF10A—round; MCF-7—mass; MDA-MB-468—
grape-like; and MDA-MB-231—stellate) were plated 
onto Matrigel and grown for 7 days. Medium ± H200 
Ab was replaced every 3–4 days. MCF10A cells formed 
small colonies of cells and appeared unaffected by the 
presence of the antibody (Figure 2C—panel 1). Untreated 
MCF-7 cells formed large masses of cells but the sizes of 
the masses were significantly reduced by addition of the 
antibody (Figure 2C—panel 2). MDA-MB-468 form sparse 
grape-like colonies on Matrigel and antibody treatment 
caused significant cell death (Figure 2C—panel 3). 
MDA-MB-231 cells initially formed colonies but after 
7 days there was outgrowth of stellate colonies from these 
in the untreated cells that was not seen in the colonies 
treated with H200 antibody (Figure 2C—panel 4).
H200 treatment causes down-regulation of the 
EphB4 gene and loss of the EphB4 protein
Breast cancer cell lines MDA-MB-231, MCF-7 and 
T47D were grown to confluent monolayers and treated 
with dilutions of H200 antibody (ranging from 1/100 
down to 1/10,000) for 65 h before total RNA was extracted 
for gene expression analysis. EphB4 gene expression was 
consistently less, to nearly absent, in some cells treated 
with antibody when compared to control untreated cells 
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(Figure 2D). Western blot analysis of EphB4 protein levels 
in MCF-7 cells treated for 24, 48 or 72 h with 0.4 μg/mL 
H200 antibody showed that there was also a correlated 
reduction in EphB4 protein in these cells (Figure 2E). 
In triplicate experiments, the EphB4 protein level was 
significantly less than both control untreated cells and cells 
treated with a mouse IgG control for 72 h (Figure 2F).
Mapping the polyclonal antibody using peptide 
exclusion assays
The EphB4 polyclonal antibody was raised against 
a recombinant protein corresponding to amino acids 
201–400 mapping within an extracellular domain region 
of human EphB4 (Figure 1A). The sequence includes 
the cysteine-rich domain and the first fibronectin type 
III repeat and accordingly it was possible that several 
different antigenic regions were recognized. We chose to 
explore the cysteine-rich region in the first instance and 
designed six, 25 amino acid peptides corresponding to 
this region for antibody competition studies (Figure 3A, 
peptides 1–6). Each peptide (0.1 mg/ml) was tested 
individually over 65 h in culture for potential toxic effects 
on cancer cell growth. None of the peptides caused 
morphological, cell growth or apoptotic changes (data not 
shown), indicating that the peptides themselves were not 
toxic to the cells.
To test whether these peptides could block the cell 
death function of the EphB4 H200 Ab, a cocktail of all 
peptides (0.1 mg/ml each) was pre-incubated with EphB4 
antibody (0.4 μg/ml) for 1 h at room temperature before 
addition to a confluent monolayer of SW480 cells. No 
inhibitory Ab response was seen, even after 65 h in culture, 
indicating that one or more of the peptides was binding to 
the functional Ab in the polyclonal mix and preventing 
attachment to the native EphB4 protein expressed on the 
tumour cell surface (Figure 3B). Peptides (0.1 mg/mL) 
were then tested separately and the antibody blocking 
Figure 2: Effects of H200 pAb treatment on in vitro cell growth characteristics, gene expression and protein levels.  
(A) The H200 pAb was tested using several different cell lines of colon (SW480, SW620), breast (MDA-MB-231, MCF-7, MCF10A), 
bladder (T24, HT119), endothelial (HUVEC), prostate (PC3, LNCaP) and osteosarcoma (BTK143, MG63) origins and after 48 h a 
significant reduction in the number of viable cells, determined using a trypan blue assay, when compared with untreated control cells was 
seen for all but T24, MCF10A, LNCaP, HUVEC and MG63. (B) Antibody targeting of EphB4 inhibits tumour cell colonisation of soft agar. 
MDA-MB-231, MDA-MB-468 and MCF10A cells were suspended in soft agar in the presence of EphB4 antibody (10 μg/ml) (Ab treated) 
or PBS vehicle control (Control) administered at the time of suspension. Colonies of more than 5 cells were counted from four different low 
power fields and the results are represented graphically. (C) Treatment with H200 prevented tubular nework formation on Matrigel. MDA-
MB-468, MDA-MB-231, MCF-7 and MCF10A cells were plated on Matrigel in the presence of EphB4 antibody (10 μg/ml) (Ab treated) or 
PBS vehicle control (Control) and images representative of each assay were taken at 20× magnification after 4 days. (D)  RT-PCR analysis 
of EphB4 gene expression (PCR product = 1187 bp) in breast cancer cell lines treated with antibody or untreated (control). Expression of the 
PBGD housekeeping gene (377 bp) was used as a control for the integrity of the cDNA and relative comparison of EphB4 expression levels. 
M1 = pUC19/HpaII marker, M2 = Lambda/HindIII. (E) Western blot analysis showing that treatment with H200 causes loss of EphB4 
protein at 72 h. β-actin was detected as a loading control and the total amount of EphB4 protein normalized to this using densitometry 
(values expressed as percentage of control). (F) Graph showing effect of H200 antibody on total EphB4 levels (relative to control) with a 
significant reduction seen at 72 h ( p = 0.0001).
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response was seen (approximately 50% of that seen using 
all of the peptides together) after the addition of either 
peptide 1 or 2 (Figure 3C). The other four peptides were 
less successful at preventing the cell death effect of the 
H200 Ab. The sequences of peptides 1 and 2 overlap by 
five amino acids—GSCVV (Figure 3A). Testing peptides 
1 and 2 individually at 0.1 mg/mL would have effectively 
halved the concentration of the GSCVV sequence used 
in the first assay (0.2 mg/mL combined). Accordingly, 
a two-fold increase of either peptide 1 or peptide 2 
(to 0.2 mg/mL) was sufficient to double the concentration 
of GSCVV in the test and thereby fully block the H200 Ab 
(Figure 3D) identifying GSCCV as the core of the epitope 
through which H200 functions to induce cell death.
To confirm that this was the key sequence, a further 
peptide, named peptide 7 comprising 8 amino acids with 
the sequence AGSCVVDA was produced (Figure 3A). 
Peptide 7 was confirmed to be non-toxic to cells (data 
Figure 3: Peptide exclusion assays to map the critical epitope recognized by EphB4 H200 antibody. (A) Six 25 amino 
acid peptides were designed to the first 125 amino acids of the 200 amino acid region (201–400) recognised by the H200 antibody and 
encompassing most of the cysteine rich region (184–320). Peptide 7 spans the overlap between peptides 1 and 2. (B) Cell viability was 
determined in the presence of H200 pAb pre-incubated with a mixture of peptides 1–6 before addition to the cells (Ab+ all peptides, 
0.1 mg/ml each) and cell viability was determined using a trypan blue assay after 65 h. Viability of cells treated with the peptide blocked H200 
pAb was consistent with the level of the control PBS-treated cells (untreated). There were no viable cells after treatment with the antibody 
alone (Ab alone) for 65 h (***p < 0.001). This experiment was performed in duplicate. (C) H200 pAb was pre-incubated with 0.1 mg/ml 
of each of the peptides 1–6 individually, as indicated, before addition to the cells. At 65 h, peptides 1 and 2 restored viability to 50% of the 
control PBS-treated cells (untreated). There were no viable cells after treatment with the antibody alone (Ab alone) (*p < 0.01, **p < 0.05, 
***p < 0.001). (D) H200 pAb was pre-incubated with 0.1 mg/ml of each of the peptides 1 and 2, or 0.2 mg/ml Peptide 1, or 0.2 mg/ml 
Peptide 2 as indicated before addition to the cells. At 65 h, viability was restored to the level of the control PBS-treated cells (untreated). 
There were no viable cells after treatment with the antibody alone (Ab alone) (***p < 0.001). (E) H200 pAb was pre-incubated with 0.2 mg/
ml Peptide 7 (spans the overlapping sequence common to Peptides 1 and 2). Viability was restored to the level of the control PBS-treated 
cells (untreated). There were no viable cells after treatment with the antibody alone (Ab alone). Because the peptide 7 solution was acidic 
and this may have negatively affected the antibody binding, antibody was also pre-treated with PBS adjusted to pH 4.7. Viable cells after 
antibody pH treatment was consistent with viability the antibody untreated (Ab alone) (***p < 0.001, NS = not significant).
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not shown). This peptide used at 0.2 mg/ml effectively 
blocked the Ab response (Figure 3E). It was noticed that 
peptide 7 lowered the pH of the solution to pH 4.7 and 
because it was possible that this low pH might cause 
unfolding and therefore inactivation of the H200 Ab, in 
a control assay the pH of an H200 aliquot was lowered 
to pH 4.7 for 1 h before it was used to treat the cells. 
There was no change seen in the effectiveness of the Ab to 
decrease cell viability (Figure 3E).
Peptide 7 selected EphB4-specific antibody 
behaves as an ephrin-B2 mimetic
Peptide 7 was immobilized onto a MicroLink 
(gel matrix used to isolate interacting antibodies 
(designated H7) from the H200 polyclonal antibody 
preparation. To confirm that isolated antibodies could 
specifically identify EphB4 we again compared the 
MCF10A and MCF10A-B4 cells using Western blot 
analysis (Figure 4A). When compared with the H200 
pAb, the H7 antibody detected only a single strongly 
immunoreactive band at the predicted 120 kDa, seen in 
the MCF10A-B4 sample and less strongly in MCF10A, 
consistent with detection of the over-expressed EphB4 in 
MCF10A-B4 and the endogenous EphB4 in MCF10A. 
Extended stimulation (for 72 h) led to a loss of EphB4 
protein from the MCF-7 cells in a similar manner to that 
of the parental H200 antibody (Figure 4B and Figure 2F). 
Addition of the purified H7 antibody to MCF-7 cells 
caused an increase in EphB4 phosphorylation as soon as 
5 min after addition which was still maintained at 30 min 
suggesting that the antibody activates EphB4 signaling 
in treated cells (Figure 4C). This would suggest that the 
antibody is behaving as an ephrin-B2 mimetic as ligand 
stimulation of EphB4 normally leads to phosphorylation 
of the kinase domain, then internalization and degradation 
of the receptor. In keeping with this hypothesis, the 
AGSCVVDA sequence contains three amino acids 
that align with those of a defined third ligand interface 
region on the EphA3 receptor (Figure 4D). Comparison 
Figure 4: Peptide specific antibodies identify EphB4, cause EphB4 protein phosphorylation and degradation.  
(A) Antibodies specifically recognizing Peptide 7 were isolated from the H200 polyclonal preparation. Western blot analysis shows that these 
antibodies (H7) specifically identify EphB4 with less non-specific cross-reactivity than the H200 antibody. β-actin was used as a loading 
control. (B) Western blot and graph showing that in a similar manner to H200, the H7 antibody, tested at two different dilutions, reduces total 
EphB4 protein level with a significant reduction seen at 72 h (p = 0.0001). (C) Immunoprecipitation of cell lysates from MCF-7 breast cancer 
cells showing treatment with the H7 antibody causes phosphorylation of the EphB4 protein, seen at 5 min after addition and maintained at 
30 min (yellow box). Cells were stimulated with soluble clustered ephrin-B2-Fc ligand (eB2) as a positive control for phosphorylation with 
clustered Fc fragment only (Fc) as the negative control for this. (D) Alignment of the EphB4 sequence of peptides 1 and 2, which includes 
peptide 7 sequence AGSCVVDA (red box) with the corresponding sequence from EphA3. Asterisks identify the amino acids identified 
as contributing to the third ligand binding domain. (E) Comparison of the peptide sequence used to raise EphB4 monoclonal antibodies 
(green) with other members of the human Eph family. Amino acids identical to the EphB4 sequence are shaded in grey, homologous amino 
acids are shaded pink. The antigenic aspartic acid reside is within a red box. (F) Comparison of the peptide sequence used to raise human 
EphB4 monoclonal antibodies (green) with EphB4 sequences from other species. Amino acids identical to the human EphB4 sequence 
are shaded in grey. (G) Western blot analysis using the H200 and 13A7 antibodies with recombinant human EphB4 extracellular domain 
(rhEphB4ecd) (H) and recombinant mouse EphB4 extracellular domain Fc fusion protein (rmEphB4ecd-Fc) (M). The arrows indicate the 
position of the proteins compared to the molecular weight marker for which sizes are indicated on the left.
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with sequences of other Eph receptors shows variability 
at key residues suggesting high epitope specificity of 
the H7 antibody (Figure 4E). For example, analysis of 
the sequence using the EMBOSS antigenic prediction 
program (http://emboss.sourceforge.net/apps/release/6.0/
emboss/apps/antigenic.html) identifies the aspartic acid 
residue in the EphB4 sequence (red box in Figure 4E) as 
the key amino acid within the most antigenic sequence 
in the 200 amino acid region targeted by the H200 
antibody. Comparison with sequences from other species 
shows few differences in the amino acid sequence of the 
corresponding regions but the most differences to mouse 
EphB4 (Figure 4F) and Western blot analysis shows that 
although the H200 antibody can detect both human and 
mouse EphB4 proteins, the 13A7 antibody that targets 
the peptide 7 sequence specifically, only identified human 
EphB4 protein (rhEphB4ecd) and not murine EphB4 
protein (rmEphB4ecd-Fc) (Figure 4G).
Production and characterization of a panel 
of EphB4 monoclonal antibodies targeting 
defined epitope
A panel of murine monoclonal antibodies was raised 
to the sequence AGSCVVDAVPAPGPSLY (Figure 4E). 
These antibodies were validated to the EphB4 protein 
using several methods. Firstly, each antibody was used to 
detect cell surface expression of EphB4 in MCF-7 cells 
by flow cytometry (Figure 5A). All antibodies caused 
an increase in fluorescence of the MCF-7 cells when 
compared with mIgG labelled cells (black peak shifted to 
right of clear peak) which shows that the antibodies are 
binding to the MCF-7 cells via the EphB4 expressed by 
these cells. Differences in the shape of the peaks, with 
some antibodies showing a single peak while others 
showed two peaks, may reflect heterogeneity of EphB4 
expression levels and epitope presentation in the MCF-
7 cell population, but also the affinities of the various 
antibodies. The BerEP4 antibody that recognises the 
epithelial EpCam glycoprotein was used as a positive 
control and mIgG1a, mIgG2a and rIgG antibodies were 
used as negative controls. Antibodies were then tested 
using Western blot analysis of MCF10A-B4 lysates. 
Three antibodies, 13B11, 2D9 and 13A7, were able 
to identify denatured and reduced EphB4 protein with 
13A7 performing best in this application (Figure 5B). 
In a third validation experiment, antibodies were used 
to immunoprecipitate EphB4 from total MCF10A-B4 
protein lysates and this was then detected by Western blot 
analysis using the Zymed antibody. Several antibodies 
successfully pulled down EphB4 confirming that 
maintenance of epitope folding is important for binding of 
some antibodies (Figure 5C). Finally, antibody recognition 
of EphB4 expressed on MCF10A and MCF10A-B4 cells 
was compared using immunofluorescence. A stronger 
green fluorescence signal was seen in MCF10A-B4 
cells compared with MCF10A cells using several of 
the antibodies with 2D9, 6H4 and 11H4 performing 
particularly well (Figure 5D).
Antibody C2 reduces growth of MDA-MB-231 cells
Cell based assays testing antibodies that recognise 
a native epitope of the target protein where the effect of 
the antibody on the growth of the cells can be determined 
are an important prelude to in vivo testing. Because EphB4 
has been shown to be important to cancer cell migration 
and invasion, we screened our antibodies for their effect 
on the formation of cancer cell networks on Matrigel, a 
cell-based assay that recapitulates in vivo cell growth and 
particularly the ability of cancer cells to migrate and invade 
the extracellular matrix. In this assay, the C2 antibody best 
prevented network formation of MDA-MB-231 breast 
cancer cells in both duplicate wells with 1H4 showing a 
web-like network similar to that of the no antibody or mIgG 
controls (Figure 6A and data not shown). For this reason 
C2 was tested for its effect on the growth of established 
MDA-MB-231 murine xenografts. Based on acute tolerated 
dose (ATD) and maximum tolerated dose (MTD) studies 
performed by VivoPharm (Adelaide, Australia), the 
maximum dose of 50 mg/kg C2 antibody was chosen. 
After 18 days (with C2 treatment given every three days), 
MDA-MB-231 tumours showed a significant decrease in 
size when compared with control untreated tumours and 
this was comparable to the response of the tumours to the 
chemotherapeutic agent, Doxorubicin (Figure 6B). We 
also tested the PC3 prostate cancer cell line, which has 
been reported to over-express EphB4 endogenously and 
for which knockdown experiments have shown EphB4 
expression is required for cancer cell viability, migration 
and invasion [6]. The PC3 tumours did not respond to the 
C2 antibody (Figure 6C). Immunofluorescence using the 
antibody C2 to visualize EphB4 in MDA-MB-231 and 
PC3 cells shows that the C2-responsive MDA-MB-231 
cells express EphB4 on the surface and in the cytoplasm 
(Figure 6D) but the PC3 cells show little surface expression 
with most of the C2-recognising EphB4 co-localising with 
the endoplasmic reticulum marker calnexin (Figure 6E). 
This highlights the need for complementary development 
of a screening technique that can accurately identify patients 
with high level surface expression of EphB4 and therefore 
those most likely to benefit from a monoclonal antibody 
therapy targeting EphB4.
DISCUSSION
Monoclonal antibody therapies are proving useful in 
the treatment of diseases including cancer but the success 
of these depends on the identification of suitable target 
proteins that play important roles in cancer progression 
by contributing to the hallmarks of cancer and are 
homogenously over-expressed and accessible on the 
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surface of tumour cells [43]. EphB4 meets all of these 
characteristics in many cancer cell lines used as models 
of different epithelial cancers making it an ideal target 
for the development of new monoclonal antibody-based 
anti-cancer therapies. To date, EphB4 has been shown 
to be over-expressed in 1046 of 1318 (82%) individual 
tumour samples from a wide selection of epithelial cancers. 
Knockdown experiments using cell lines representing 
several of these epithelial cancers have shown that EphB4 
increases cancer cell viability, and contributes to migration 
and invasion [6, 11, 26–27]. Over-expression studies have 
confirmed this, showing that increasing EphB4 levels can 
confer a transformed phenotype (breast MCF10A) and an 
increased metastatic phenotype (prostate cancer 22Rv1) 
[28]. Importantly, both phenotypes can be restrained by 
stimulation with ephrin-B2 proving that over-production of 
EphB4 contributes in a ligand-independent mechanism and 
that ligand-dependent stimulation is tumour suppressive.
It is this dichotomy of EphB4 signaling that 
makes this receptor tyrosine kinase a unique target for 
the development of anti-cancer therapies. Successful 
approaches will use therapies that 1) mimic the ephrin-B2 
ligand and stimulate tumour suppressive signaling 
pathways, 2) cause internalisation and degradation of 
EphB4 preventing further ligand-independent signaling 
that is tumour promoting and 3) can block further de novo 
EphB4 production. This is in clear contrast to approaches 
used to target other receptor tyrosine kinases such as 
EGFR and HER2, where prevention of receptor interaction 
with ligand (soluble growth factors) or inhibition of 
Figure 5: Validation of the EphB4-specificity of the epitope targeting monoclonal antibodies and their use for detecting 
EphB4 using different techniques. (A) Monoclonal antibodies were screened using flow cytometry to detect EphB4 expression on 
MCF-7 cells. The shift in peak fluorescence to the right (black filled) is compared with the matched isotype control (mIgG1, mIgG2a 
or rIgG) (red line) and is due to antibody binding. The H200 was used for comparison and the BerEP4 antibody that detects the epithelial 
glycoprotein EpCam was used as the positive control. (B) Western blot analysis showing that denatured and reduced EphB4 (120 kDa) 
can be identified using antibodies 13A7, 13B11 and 2D9. The Life Technologies “Zymed” monoclonal antibody was used as the positive 
control. (C) EphB4 was immunoprecipitated from total protein lysates using several of the monoclonal antibodies. EphB4 was identified in 
the immunoprecipitated sample via Western blot analysis using the Zymed antibody. (D) Immunofluorescence comparing EphB4 detection 
(green) in the MCF10A and MCF10A-B4 cells using the monoclonal antibodies. Bar = 80 μm.
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tyrosine kinase activity, using small molecules that sit in 
the ATP binding pocket, are proving successful [44–45]. 
It is possible that “leaky” tyrosine kinase inhibitors may 
also interact with EphB4, blocking the tumour suppressive 
signaling pathways and this may contribute to resistance 
seen in tumours that co-express EphB4 with the intended 
target receptor [46–47].
Phosphorylation and degradation of EphB4 in 
response to H200 addition suggest that the antibody can 
mimic the actions of the ephrin-B2 ligand. The mapped 
epitope sequence AGSCVVDA corresponds to amino 
acids 220 to 227 in the EphB4 extracellular domain and 
is at the N-terminal of the cysteine-rich region. A study 
by Smith et al (2005) shows that the N-terminal sequence 
of the cysteine-rich region contains a novel Eph/ephrin 
interaction interface [48]. Amino acid residues targeted 
by mutations within the region 208 to 232 of EphA3 
define this third interface. A comparison of the amino acid 
sequences from EphA3 and EphB4 show that the sequence 
of the third Eph/ephrin interface falls entirely within the 
sequence defined by the overlapping EphB4 peptides 
1 and 2. Furthermore, two of the amino acids targeted 
by mutations to define the EphA3 interface, V231D 
and N232I, are within the 8 amino acid sequence that is 
defined as the epitope through which the EphB4 H200 
antibody acts to cause tumour cell death. This provides 
further support for our hypothesis that the H200 functional 
antibody mimics the ligand.
Figure 6: Antibody C2 is effective against MDA-MB-231 cells with surface EphB4 expression. (A) Each antibody was 
tested for their ability to prevent tubular network formation of MDA-MB-231 cells grown on Matrigel. C2 was the most effective in 
duplicate wells. (B) Tumour growth data for MDA-MB231 xenograft tumours treated daily for 18 d with 50 mg/kg anti-EphB4 antibody 
C2 (red squares), positive control chemotherapeutic Doxorubicin™ (green triangles) or untreated (PBS) control group (blue diamonds). 
The C2 monoclonal antibody significantly reduces the size of tumours by 18 days (p < 0.001) and even performs better than Doxorubicin™ 
over this time course. (C) Tumour growth data for PC3 xenograft tumours treated daily for 18 d with 50 mg/kg anti-EphB4 antibody C2 
(red squares), positive control chemotherapeutic Taxol (green triangles) or untreated (PBS) control group (blue diamonds). The C2 antibody 
does not affect PC3 tumour growth. (D) Immunofluorescence localization of EphB4 (green) in MDA-MB-231 cells using the C2 antibody. 
Phalloidin-TRITC (red) stains F-actin, DAPI (blue) stains the nucleus. Bar = 10 μm. (E) Immunofluorescence localization of EphB4, using 
the C2 antibody (green), and the endoplasmic reticulum marker calnexin (red) in PC3 cells. DAPI (blue) stains the nucleus. Bar = 10 μm.
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Addition of H200 to cancer cells in vitro causes a 
decrease in EphB4 gene expression identifying a negative 
feedback loop. Knockdown experiments using EphB4 
targeting siRNA sequences have shown that EphB4 
contributes to cancer cell viability, migration and invasion 
identifying the key roles for EphB4 in cancer cells. In a 
manner consistent with this, H200 stimulation decreases 
cancer cell numbers and this correlates with an increase in 
caspase-3 activity indicating activation of apoptosis. H200 
stimulation also prevents colony formation in soft agar 
and the formation of tubular networks on Matrigel, assays 
providing an in vitro indication of a negative effect of H200 
on migration and invasion ability. This shows that the H200 
antibody targets the hallmark roles EphB4 plays in cancer, 
justifying use of monoclonal antibodies for the development 
of new therapies against EphB4 positive cancers.
It is interesting that the H200 antibody only 
caused in vitro cell death after the cells had grown to a 
confluent monolayer. A similar response was reported by 
Carles–Kinch et al (2002) who identified an EphA2 mAb 
that recognizes a binding site present only in EphA2-
positive cancer cells and reverses metastatic behaviour 
by activating the high levels of EphA2 on a tumour cell 
surface [49]. A coincident growth inhibitory effect was 
also only noticed after the cells had reached confluence. 
In both of these cases it would appear that a further 
requirement for this response is close proximity between 
neighbouring cells. Treatment with the H200 antibody 
caused the confluent monolayer of cells to lift from the 
dish as a fragile sheet. This shows that although the cells 
lost attachment to the dish, they maintained weak cell 
to cell attachment. Noren et al (2009) report that EphB4 
kinase activity inhibits integrin-dependent cell adhesion 
[2]. Although not determined here, it is possible that a 
consequence of treatment with H200 is stimulation of 
EphB4 signaling pathways that alter integrin expression 
and/or activity. Recently Lehtinen et al (2013) reported 
that EphB4 silencing correlated with reduced expression 
of the intermediate filament protein vimentin and suggest 
EphB4 is a novel regulator of vimentin expression [25]. 
Vimentin is often upregulated during cancer progression 
and plays a key role in the epithelial to mesenchymal 
transition and cell invasion [50]. H200-induced loss of 
EphB4 might also cause loss of vimentin and this might 
contribute to the resultant decrease in invasion.
Our results show that a monoclonal antibody, 
designed to target the sequence mapping to a possible 
third ligand interacting domain within the cysteine-rich 
region of EphB4, and functioning as a ligand mimetic, 
can reduce/inhibit the in vivo growth of cancer cells that 
express EphB4 on the cell surface. This is consistent with 
reports from the literature that describe anti-cancer effects 
of EphB4 antibodies targeting other epitopes [37]. For 
example, two antibodies, MAb131 and MAb47, targeting 
separate epitopes in the first and second fibronectin 
type III (FIII) repeats of EphB4 respectively, have been 
developed and tested with some success in vivo using 
several different models of epithelial cancers [37]. The 
mechanisms through which these antibodies function is 
unlikely to be as direct ligand mimetics as FIII repeats 
are thought to have roles in protein-protein interactions 
especially in the extracellular matrix [51]. MAb131 can 
induce EphB4 degradation and inhibits endothelial tube 
formation in vitro and also inhibits the growth of EphB4-
positive tumour xenografts [37]. Contrastingly, MAb47 
had no effect on the level of EphB4 and inhibits the growth 
of both EphB4-positive and EphB4-negative xenograft 
models which suggests this antibody does not specifically 
target EphB4 but is instead functioning through another 
FIII-containing tumour protein [37].
With roles in regulating/modifying the important 
cancer progression hallmarks of viability, migration 
and invasion and common over-expression in up to 
82% of epithelial cancers, EphB4 is a key target for the 
development of anti-cancer therapies. We demonstrate here 
that antibodies that target a ligand binding epitope cause 
phosphorylation and degradation of EphB4 in a ligand-
mimetic manner and may prove particularly effective.
METHODS
Cell culture and antibodies
Cell lines used in this study were purchased 
from the American Type Culture Collection (ATCC) 
(Rockville, MD) and were cultured according to the 
ATCC recommendations in media and additives purchased 
from Life Technologies (Victoria, Australia). Three 
commercially available human EphB4-specific polyclonal 
antibodies EphB4 (N-19), EphB4 (H-200) and EphB4 
(C-16) were purchased from Santa Cruz Biotechnology 
(Dallas, TX). An additional rabbit polyclonal antibody (S) 
recognizing human EphB4 (C-terminal) was a gift from 
Dr Andrew Ziemiecki, University of Bern, Switzerland 
[52]. For immunoprecipitation and Western blot analysis 
the C-terminal EphB4-specific mouse monoclonal antibody 
(Zymed, Life Technologies) and the phosphotyrosine 
specific 4G10 antibody (EMD Millipore, Billerica, MA) 
were used. The anti-human actin murine monoclonal 
antibody was from Abcam (Cambridge, MA). Secondary 
antibodies included a peroxidase-conjugated goat anti-
mouse secondary antibody (Pierce, Thermo Fisher 
Scientific, Waltham, MA), a donkey anti-rabbit secondary 
antibody (Pierce) and Alexa Fluor® 488 or Alexa Fluor® 
568, goat anti-mouse IgG (H + L) or goat anti-rabbit IgG 
(H + L) antibodies (Life Technologies).
RNA isolation and relative quantitation of 
EphB4 expression
RNA was isolated from cell lines using TrizolTM 
solution according to the manufacturer’s recommendations 
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(Life Technologies) and quantitated using a Nanodrop 
Spectrophotometer (Thermo Fisher Scientific). Total 
RNA was reverse transcribed using Superscript III reverse 
transcriptase (Life Technologies). Primers specific to EphB4 
[8] and the housekeeping gene porphobilinogen deaminase 
(PBGD) [7] were used to PCR amplify gene-specific 
fragments from cDNA made using total RNA extracted 
from the various cell lines. PCR reactions were performed 
in a PTC-200 thermocycler (Perkin Elmer, Waltham, 
MA) with the following conditions: 2 μl cDNA template, 
1.5 mM MgCl2, 200 μM each dNTP, 50 ng of each forward 
and reverse primer, and 0.5 units of Hot Star Taq polymerase 
in 1× PCR buffer (Qiagen, Limberg, Netherlands). Cycling 
conditions included an initial denaturation at 95°C for 
15 min, followed by 40 cycles of 95°C for 30 sec, 58–68°C 
for 30 sec and 74°C for 30 sec, with a final extension of 
74°C for 7 min. Amplification products were visualised 
by ethidium bromide staining following separation by 
electrophoresis through 1% agarose gels.
Protein isolation, SDS-PAGE, western blotting 
and immunoprecipitation
Protein was isolated by direct lysis of cells grown 
in culture using RadioImmuno-Precipitation Assay (RIPA) 
buffer (15 mM HEPES, pH 7.4, 2% Triton X-100, 145 mM 
NaCl, 0.1 mM MgCl2, 10 mM EGTA, 1 mM sodium 
orthovanadate, 1 mM PMSF, aprotinin) supplemented with 
Complete protease inhibitors (Complete Mini-EDTA Free, 
Roche, Mannheim, Germany). Protein concentrations were 
determined using a BCA assay. Immunoprecipitation was 
performed using 4 μg antibody and Protein G Sepharose 
using the Immunoprecipitation Starter Kit and the 
manufacturer’s instructions (GE Healthcare, Rydalmere, 
NSW). Proteins were separated using 10% SDS–PAGE 
gels then transferred onto BioTrace™ NT nitrocellulose 
membrane (Pall, Pensacola, FL). Membranes were blocked 
with Western blocking reagent (Roche) before incubation 
with primary antibodies to EphB4 including H200 
(1:1000) and Zymed (1:1000) and to actin (1:10,000). 
Immunoreactivity was detected using the Amersham™ 
ECL Plus Chemiluminescence kit (GE Healthcare) and 
exposed to SuperRX X-ray film (Fuji Film Corporation, 
Japan).
Cell viability assay using trypan blue exclusion
Cells were grown to full confluence before the 
addition of antibodies and incubation at 37°C for specified 
times ranging from 5 min to several days. The percentage 
of viable to non-viable cells was determined using trypan 
blue exclusion and light microscopy. Adherent cells 
were collected from the culture vessels using trypsin and 
combined with medium containing detached cells before 
all cells were collected using centrifugation at 1000 rpm 
for 5 min. The cell pellet was resuspended in 0.2% Trypan 
blue (Sigma, St Louis, MO) in PBS and after 5 min, the 
number of viable (unstained) and non-viable (stained) 
cells were counted using a haemocytometer.
Apoptosis and cytotoxicity assays
Caspase-3 activity was determined as an indicator 
of apoptosis. Detached cells were washed from plates with 
500 μl PBS and collected by centrifugation. Adherent cells 
were lysed using a buffer containing 5 mM Tris HCl pH 
7.4, 5 mM EDTA and 5% NP-40 and the lysate removed 
to the tube containing the corresponding cell pellet. 
Samples were frozen at –20°C until needed for processing. 
A 50 μl aliquot of the cell lysis was added to 1 ml of 
caspase substrate buffer containing 50 mM HEPES, 10% 
sucrose and 0.1% CHAPS with 10 mM DTT and 1 μl/ml 
of the caspase-3 fluorescent substrate Ac-DEVD-AFC 
(Calbiochem, EMD Millipore). Reactions were incubated 
at room temperature overnight prior to measurement 
of caspase activation using a spectrofluorimeter with 
excitation at 400 nm and emission at 505 nm. Apoptosis 
was also measured by Annexin-V and propidium iodide 
staining followed by flow cytometry using an Annexin-V 
FLUOS kit (Roche). Lactate dehydrogenase (LDH) 
release, as a measure of cytotoxicity, was determined 
using the Cytotox 96® Non-Radioactive Cytotoxicity 
Kit (Promega, Madison, WI).
Assay of anchorage independent growth using 
soft agar
Colony formation in soft agar was performed 
as described by Clark et al (1996) [32]. Cells were 
resuspended in a molten solution of 0.3% agar (Merck, 
EMD Millipore) with the appropriate medium, 
depending on the cell line being used for the assay, 
and set onto a 0.8% medium-agar base. Antibody 
(10 μg/ml) or PBS vehicle was included in the top agar 
solution. Colony formation after 12 days was visualised 
microscopically using a Nikon Eclipse E800 light 
microscope at 20× magnification and images recorded 
using a Diagnostic Instruments Camera Model 2.3.1 and 
Image-Pro Plus 4.1 for Windows.
Assay of network formation on Matrigel
The growth of cells on Matrigel was analyzed as 
described in Giunciuglio et al (1995) [33]. Briefly, 260 μl 
of 10 mg/ml Matrigel (BD Biosciences, Bedford, MA) 
was polymerized in each well of a 24-well tissue culture 
plate for 30 min at 37°C. The matrigel layer was then 
dehydrated overnight and re-hydrated 30 min before use 
with 260 μl of cell culture medium. Excess medium was 
carefully removed before the addition of 5 × 104 cells with 
either the H-200 antibody (10 μg/ml) or vehicle (PBS). 
Cells were incubated on Matrigel for 72 h under normal 
tissue culture conditions and network formation was 
assessed using a Nikon Eclipse E800 light microscope and 
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recorded digitally using a SciTech camera (Melbourne, 
Australia). Images were processed using SPOT Advanced 
Software Version 3.5.
Epitope identification using a peptide exclusion 
approach
Six, consecutive 25 amino acid peptides that 
overlapped by five amino acids and corresponded to amino 
acids 201–326 of the extracellular domain of EphB4 were 
manufactured commercially by Auspep (Sydney, Australia). 
These were reconstituted to a stock solution of 10 mg/ml 
for use at a range of concentrations from 0.1 to 0.2 mg/ml. 
Peptides were pre-incubated with 0.4 μg/ml EphB4 H-200 
antibody in DMEM for 1 h at room temperature before 
addition to confluent monolayers of cells. Cells were 
grown under normal culture conditions for up to 72 h before 
collection for viability and apoptosis assays.
Peptide affinity purification of antibody
A peptide corresponding to the mapped epitope 
(Peptide 7) was made commercially by Auspep. This was 
coupled to a gel matrix using the MicroLink™ Peptide 
Coupling Kit (Pierce) and the manufacturer’s instructions 
then used to purify antibodies that bound to the epitope 
from the H200 polyclonal antibody mix.
Immunofluorescence
Immunofluorescence was performed using the method 
reported in Rutkowski et al (2012) (28). Briefly, 1 × 105 
cells were seeded onto cover slips and allowed to attach 
for 24 h before being fixed using 4% paraformaldehyde 
and permeabilised using 0.3% Triton X-100. Non-specific 
binding was blocked using 10% goat serum before addition 
of antibodies overnight at 4°C. After washing, bound primary 
antibody was detected using a secondary antibody conjugated 
to a fluorescent tag. In some experiments phalloidin 
conjugated to tetramethyl rhodamine isothiocyanate (TRITC) 
(Sigma, St. Louis, MO) was used to stain F-actin. Cover 
slips were mounted on glass slides using Prolong Gold 
Antifade with 4,6-diamidino-2-phenylindole DAPI (Life 
Technologies) and cells were visualised using a Leica SP5 
spectral scanning confocal microscope. To identify EphB4 
specific staining, control samples included one to which 
an irrelevant mouse IgG was added, another to which the 
secondary antibody alone was added and a third to which no 
antibody was added.
Production of monoclonal antibodies
Five 6–8 week old Balb/c mice were immunized 
three times with a 21 amino acid containing the target 
epitope PVAGSCVVDAVPAPGPSPSLYK conjugated at 
the C-terminus to keyhole limpet hemocyanin (KLH). The 
first immunisation was performed using Freund’s complete 
adjuvant and the others with Freund’s incomplete 
adjuvant. Antibody titre was determined using a sample 
of blood collected by an incision of the tail vein and 
using an ELISA based assay for immunoreactivity to the 
peptide as described below. Hybridomas were produced 
by PEG-mediated fusion of splenocytes of the mouse with 
the highest titre with SP2/0 myeloma cells and selected 
in hypoxanthine-aminopterin-thymidine (HAT) medium. 
Eight individual monoclonal populations of hybridomas 
(1H4, 2D9, 5B7, 6H4, 9B7, 11H4, 13A7 and 13B11) 
each producing an antibody specific to the peptide, were 
selected by ELISA (method described below). Two further 
hybridomas (C1 and C2) were produced commercially 
(Millipore) using the same immunogen. All hybridomas 
were maintained in BD CellTM MAb Medium Quantum 
Yield (BD Biosciences) and antibodies were purified from 
the medium by MAbSA (Adelaide, Australia).
Enzyme-linked immunosorbent assay
Peptides, recombinant proteins or control solutions 
were used to coat the bottom of wells of 96-well Nunc 
Maxisorp ELISA plates (eBioscience, San Diego, CA). 
Non-specific binding sites were blocked using 5% bovine 
serum albumin (BSA) before the addition of hybridoma 
supernatant or antibody solution, and incubation overnight 
at 4°C. Bound antibodies were detected using a peroxidase-
coupled secondary antibody, added after washing for 1 h at 
room temperature. The substrate o-Phenylenediamine 
dihydrochloride (SIGMAFAST TM OPD) was then converted 
by peroxidase activity to a coloured product that is measured 
at 492 nm in the presence of urea using an xMarkTM 
Microplate Absorbance spectrophotometer (BioRad).
Flow cytometry
Cells were removed from the dish with Versene and 
washed twice with fresh medium before counting using 
a haemocytometer. Cells were resuspended at 1 × 105 
cells/mL in Binding buffer (0.5 M HEPES, pH 7.4; 2% 
fetal calf serum; 2 μg/mL IgG) and 8 μg of primary 
antibody added before incubation on ice for 1 h. Cells were 
washed twice in cold Binding buffer before the addition of 
0.5 μg of goat anti-mouse-FITC secondary antibody and 
incubation on ice for 1 h. Cells were again washed twice 
in ice-cold Binding buffer and the pellet resuspended in 
600 μL of FACS Fix solution (1% paraformaldehyde and 
1% glucose in PBS). Analysis of the cells was performed 
using a Beckman Coulter FC500 MPL Flow cytometer.
In vivo tumour growth studies
Testing of the C2 antibody using human xenograft 
tumour models of breast cancer (using MDA-MB-231 
cells) and prostate cancer (using PC3 cells) were performed 
by vivoPharm (Adelaide, Australia). Initially, the acute 
tolerated dose (ATD) of the C2 antibody was determined 
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using four groups of four mice, treated with 50 mg/kg, 
20 mg/kg, 7 mg/kg and 0 mg/kg antibody (PBS vehicle 
only). Mice were observed for 7 days for signs of weight 
loss and changes to behavior. The maximum dose of C2 for 
which no effects were noted was 50 mg/kg and this dose was 
then used to determine the maximum tolerated dose (MTD). 
In this test, four mice in four groups were given either 
the maximum dose of 50 mg/kg C2 antibody (as per the 
ATD test), 80% of that dose (40 mg/kg), 60% of that dose 
(30 mg/kg) or remained untreated (PBS vehicle only). The 
mice were treated with this dose of C2 every day for 7 days 
and were observed for any negative effect. The maximum 
dose for which no effects are noted (50 mg/kg) was then 
used for testing the efficacy of the C2 antibody against 
xenograft tumour growth in mice. MDA-MB-231 or PC3 
cells were implanted subcutaneously into the right flank 
of athymic (nu/nu) mice and tumours allowed to establish 
until they reached a volume of 80–120 mm3 before 
treatments began. Treatments included C2 antibody at 
50 mg/kg, doxorubicin at 1.91 mg/kg as a positive control 
chemotherapeutic against MDA-MB-231 tumours, and 
Taxol at 10 mg/kg as a positive control chemotherapeutic 
against PC3 tumours. Each treatment was given three times 
weekly by intraperitoneal injection. Subcutaneous tumours 
were measured twice weekly using Vernier calipers and the 
tumour volume calculated using the formula V = L × W2/2, 
where V = volume, L = length and W = width. Mice were 
euthanized at the end of the experiment or when tumours 
grew > 1000 mm3 by cervical dislocation. Experiments 
were performed with animal ethics approval from the 
University of Adelaide, Australia.
Statistical analysis
All results are expressed as mean ± SD. Differences 
between experimental groups were analysed by unpaired 
Student’s t-test. p values < 0.05 were considered 
statistically significant.
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